The selective immune modulator activates the neuroprotective transcription factor nuclear receptor related 1 (Nurr1), which is associated with direct neuroprotective properties. Additionally, ...
5d
NEW YORK, November 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...
A pipeline candidate from NurrOn Pharmaceuticals (originating from Harvard Medical School's Molecular Neurobiology Laboratory ...
In September, we hosted an in person MS R&D day, which featured two world renowned industry experts, Dr. Francesca Montarolo, Biologist and Leading MS and Nurr1 Target Expert from the Neuroscience ...
Immunic to Participate in Industry, Scientific and Investor conferences in November ...
Retinoic acid (RA) is involved in the induction of neural differentiation, motor neuron axon outgrowth and neural patterning during development, but there is growing evidence that RA could be used ...
The selective immune modulator activates the neuroprotective transcription factor nuclear receptor related 1 (Nurr1), which is associated with direct neuroprotective properties. Additionally ...
Quarter Results07.11.2024 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic, Inc. Reports Third Quarter 2024 Financial Resultsand Provides Corporate Update– ...
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback